You are here: Industry Insights > Hemophilia

News List

Roche’s Hemlibra continued to substantially reduce bleeds in people with haemophilia A with inhibito roche
December 11, 2017
Newly approved Hemlibra demonstrated superior efficacy compared to prior treatment with bypassing agents as prophylaxis or on-demand
Roche's haemophilia A drug shows meaningful bleed control in P3 pharmafile
December 08, 2017
Roche Has New Phase 3 Clinical Trial of Hemophilia A for Helimbra (emicizumab) for Patients Under 12
FDA Approves Genentech's Hemlibra, the First Drug in 20 Years for Hemophilia A With Inhibitors biospace
November 17, 2017
The U.S. Food and Drug Administration approved Genentech’s hemophilia drug Hemlibra (emicizumab-kxwh), which will be used to prevent or reduce the frequency of bleeding episodes in certain patients.
Shire’s haemophilia A gene therapy wins Orphan status pharmatimes
October 27, 2017
Shire’s gene therapy candidate SHP654, an investigational factor VIII gene therapy for the treatment of haemophilia A, has been awarded Orphan Dr
Bioverativ taps patient social network for input on hemophilia trial design fiercepharma
August 25, 2017
Bioverativ designed a hemophilia drug trial to address newly unearthed unmet needs, by gauging pain in addition to bleeding.
FDA approves new Novo Nordisk treatment for patients with Hemophilia biospectrumasia
June 02, 2017
REBINYN is indicated for on-demand treatment and control of bleeding episodes, and the perioperative management of bleeding in adults and children with hemophilia B
‘World Hemophilia Day’ marked by release of data pharmafile
April 21, 2017
‘World Hemophilia Day’ occurred on 17 April and the day was marked by the release of data from two companies...
Grifols donates 140 Million international units of blood clotting factors to the World Federation of pharmaasia
April 21, 2017
Helping treat tens-of-thousands of patients in developing countries by renewing partnership with WFH, reaffirming commitment to improving patient's lives.
Roche's Hemophilia A Drug Positive in Second Phase III Study nasdaq
April 18, 2017
Roche Holding AG 's RHHBY unit Genentech announced positive interim results from the Phase III HAVEN 2 study ...
Biogen completes separation of global hemophilia business, Bioverativ cphi-online
February 06, 2017
Bioverativ common stock to be traded on the NASDAQ global select market.

Previous page 1 2 3 Next page